Serum magnesium level and arterial calcification in end-stage renal disease.
In this paper we examine the relationship of serum levels of Ca, P, Ca X P, P/Mg, Ca X P/Mg, alkaline phosphatase, and iPTH to the development or regression of peripheral arterial calcifications (AC) in 44 patients with end-stage renal disease being treated by continuous ambulatory peritoneal dialysis (CAPD). The average follow-up time of this longitudinal study was 27 months (range 6-67 months). The patients were divided into two groups: Group A, those showing one or more increases of AC; and Group B, patients in whom AC either did not develop or decreased during the follow-up. There was no significant difference in serum Ca, P, Ca X P, alkaline phosphatase of iPTH between the two groups. However, serum Mg was significantly lower in Group A than in Group B (2.69 +/- 0.52 and 3.02 +/- 0.51 mg/dl, respectively, P less than 0.001), while the ratios P/Mg and Ca X P/Mg were significantly higher. Our observations suggest that in end-stage renal disease hypermagnesemia may retard the development of arterial calcifications.
Meema
H E
HE
Department of Radiology, Toronto Western Hospital, Ontario, Canada.
Oreopoulos
D G
DG
Rapoport
A
A
D000328:Adult; D000368:Aged; D000792:Angiography; D001158:Arteries; D001862:Bone Resorption / Q000150:complications; D002114:Calcinosis / Q000097:blood / Q000150:complications* / Q000000981:diagnostic imaging; D002118:Calcium / Q000097:blood; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications; D008137:Longitudinal Studies; D008274:Magnesium / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D014652:Vascular Diseases / Q000097:blood / Q000150:complications* / Q000000981:diagnostic imaging
D010281:Parathyroid Hormone; D010758:Phosphorus; D008274:Magnesium; D002118:Calcium